ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
61,468.60
-0.55%
S&P 500
5,469.30
0.39%
Dow Jones
39,112.16
-0.76%
US Dollar vs Yen
159.9635
0.17%
Brent Oil
84.665
0.57%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Travere Therapeutics Inc (TVTX)

  7. Travere Therapeutics Inc (TVTX) ニュース

TVTX

Travere Therapeutics (TVTX)

Travere Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:TVTX
日付受信時刻ニュースソース見出しコード企業名
2024/06/1505 : 05Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:TVTXTravere Therapeutics Inc
2024/06/1206 : 00GlobeNewswire Inc.Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TVTXTravere Therapeutics Inc
2024/05/1606 : 00GlobeNewswire Inc.Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TVTXTravere Therapeutics Inc
2024/05/1405 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TVTXTravere Therapeutics Inc
2024/05/1105 : 06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TVTXTravere Therapeutics Inc
2024/05/1105 : 06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TVTXTravere Therapeutics Inc
2024/05/1105 : 05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TVTXTravere Therapeutics Inc
2024/05/1105 : 05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TVTXTravere Therapeutics Inc
2024/05/1105 : 05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TVTXTravere Therapeutics Inc
2024/05/1105 : 05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TVTXTravere Therapeutics Inc
2024/05/1005 : 30GlobeNewswire Inc.Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association CongressNASDAQ:TVTXTravere Therapeutics Inc
2024/05/0905 : 30GlobeNewswire Inc.Travere Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:TVTXTravere Therapeutics Inc
2024/05/0705 : 46Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TVTXTravere Therapeutics Inc
2024/05/0705 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TVTXTravere Therapeutics Inc
2024/05/0705 : 01GlobeNewswire Inc.Travere Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:TVTXTravere Therapeutics Inc
2024/04/3005 : 30GlobeNewswire Inc.Travere Therapeutics to Report First Quarter 2024 Financial ResultsNASDAQ:TVTXTravere Therapeutics Inc
2024/04/2420 : 05GlobeNewswire Inc.Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA NephropathyNASDAQ:TVTXTravere Therapeutics Inc
2024/04/2416 : 00PR Newswire (Canada)CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA NephropathyNASDAQ:TVTXTravere Therapeutics Inc
2024/04/2416 : 00PR Newswire (US)CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA NephropathyNASDAQ:TVTXTravere Therapeutics Inc
2024/04/0505 : 30GlobeNewswire Inc.Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians InternationalNASDAQ:TVTXTravere Therapeutics Inc
2024/04/0405 : 30GlobeNewswire Inc.Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses AssociationNASDAQ:TVTXTravere Therapeutics Inc
2024/03/1406 : 00GlobeNewswire Inc.Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TVTXTravere Therapeutics Inc
2024/03/1120 : 05GlobeNewswire Inc.Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)NASDAQ:TVTXTravere Therapeutics Inc
2024/02/2706 : 30GlobeNewswire Inc.Travere Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:TVTXTravere Therapeutics Inc
2024/02/2406 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TVTXTravere Therapeutics Inc
2024/02/2321 : 05GlobeNewswire Inc.Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA NephropathyNASDAQ:TVTXTravere Therapeutics Inc
2024/02/2316 : 00PR Newswire (Canada)CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathyNASDAQ:TVTXTravere Therapeutics Inc
2024/02/2316 : 00PR Newswire (US)CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathyNASDAQ:TVTXTravere Therapeutics Inc
2024/02/2022 : 10Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:TVTXTravere Therapeutics Inc
2024/02/1606 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TVTXTravere Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:TVTX

最近閲覧した銘柄

BIT
UV4KRZ
Unicredit Bank
BIT
F18077
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有